Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Sees Significant Increase in Short Interest

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 162,900 shares, an increase of 74.0% from the October 15th total of 93,600 shares. Based on an average trading volume of 221,600 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.3% of the shares of the company are short sold.

Chemomab Therapeutics Stock Performance

CMMB remained flat at $1.74 during trading on Thursday. 209,964 shares of the company’s stock traded hands, compared to its average volume of 186,728. Chemomab Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.55. The stock has a 50 day moving average price of $1.57 and a 200 day moving average price of $1.26. The stock has a market cap of $24.99 million, a price-to-earnings ratio of -1.53 and a beta of 0.53.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period in the prior year, the firm earned ($0.72) EPS. Analysts expect that Chemomab Therapeutics will post -0.9 earnings per share for the current fiscal year.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).